Abstract:Hepatocellular carcinoma (HCC) is the predominant form of liver cancer and has long been among the top three cancers that cause the most deaths worldwide. Therapeutic options for HCC are limited due to the pronounced tumor heterogeneity. Thus, there is a critical need to study HCC from a systems point of view to discover effective therapeutic targets, such as through the systematic study of disease perturbation in both regulation and metabolism using a unified model. Such integration makes sense for cancers as it links one of the dominant physiological features of cancers (growth, which is driven by metabolic networks) with the primary available omics data source, transcriptomics (which is systematically integrated with metabolism through the regulatory-metabolic network model). Here, we developed an integrated transcriptional regulatory-metabolic model for HCC molecular stratification and the prediction of potential therapeutic targets. To predict transcription factors (TFs) and target genes affecting tumorigenesis, we used two algorithms to reconstruct the genome-scale transcriptional regulatory networks for HCC and normal liver tissue. which were then integrated with corresponding constraint-based metabolic models. Five key TFs affecting cancer cell growth were identified. They included the regulator CREB3L3 , which has been associated with poor prognosis. Comprehensive personalized metabolic analysis based on models generated from data of liver HCC in The Cancer Genome Atlas revealed 18 genes essential for tumorigenesis in all three subtypes of patients stratified based on the non-negative matrix factorization method and two other genes ( ACADSB and CMPK1 ) that have been strongly correlated with lower overall survival subtype. Among these 20 genes, 11 are targeted by approved drugs for cancers or cancer-related diseases, and six other genes have corresponding drugs being evaluated experimentally or investigationally. The remaining three genes represent potential targets. We also validated the stratification and prognosis results by an independent dataset of HCC cohort samples (LIRI-JP) from the International Cancer Genome Consortium database. In addition, microRNAs targeting key TFs and genes were also involved in established cancer-related pathways. Taken together, the multi-scale regulatory-metabolic model provided a new approach to assess key mechanisms of HCC cell proliferation in the context of systems and suggested potential targets.

Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers

Functional Genomic Studies: Insights into the Pathogenesis of Liver Cancer

Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma

Metabolic reprogramming and its clinical implication for liver cancer

Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma

Genetic Profiling of Intrahepatic Cholangiocarcinoma and Its Clinical Implication in Targeted Therapy.

A Novel Prognostic Model for Hepatocellular Carcinoma Based on Pyruvate Metabolism-Related Genes

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA

Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC

Integrated regulatory-metabolic network model reveals critical mechanism and potential targets for Hepatocellular Carcinoma

Genomic and Transcriptomic Profiling of Hepatocellular Carcinoma Reveals a Rare Molecular Subtype

Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma

Emerging Role of Molecular Diagnosis and Personalized Therapy for Hepatocellular Carcinoma

Distinctive Metabolism-Associated Gene Clusters That Are Also Prognostic in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma

Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma

Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma

Primary Liver Cancers, Part 2

Mechanistic Modeling of Gene Regulation and Metabolism Identifies Potential Targets for Hepatocellular Carcinoma

Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma

Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.

Genomic and immune landscape in hepatocellular carcinoma: Implications for personalized therapeutics